Novagant Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2002
2003
2013
2014
Cost of Goods Sold (COGS) incl. D&A
-
-
-
1.10
Gross Income
-
-
-
1.10
SG&A Expense
-
-
141.20
31.60
EBIT
117.30
123.30
142.30
32.70
Unusual Expense
-
-
-
32.40
Interest Expense
-
-
3.50
-
Pretax Income
117.30
123.30
145.80
65.00
Consolidated Net Income
117.30
123.30
145.80
65.00
Net Income
117.30
123.30
145.80
65.00
Net Income After Extraordinaries
117.30
123.30
145.80
65.00
Net Income Available to Common
117.30
123.30
145.80
65.00
EPS (Basic)
124.20
32.40
0.00
0.00
Basic Shares Outstanding
0.90
4.10
67,522.80
77,371.60
EPS (Diluted)
123.53
30.25
0.00
0.00
Diluted Shares Outstanding
0.90
4.10
67,522.80
77,371.60
EBITDA
117.30
123.30
141.20
31.60
Other Operating Expense
117.30
123.30
-
-

About Novagant

View Profile
Address
1600 Broadway
Denver Colorado 80202
United States
Employees -
Website http://www.novagant.com
Updated 07/08/2019
Novagant Corp., is a development stage company, which intends to operate as a holding company. It focuses on the manufacture and trade of equipment for the enhancement of medical cannabis industry. Its products include Alkanna light, Glavape medical cannabis vaporizer, and GoldenCBD capsules.